Ding Qianjin, Niu Lijun, Tong Chenguang
Department of Neurosurgery, Xinxiang Center Hospital, Xinxiang, China.
General Medicine Department, The 9th Medical Center, Chinese PLA General Hospital, Beijing, China.
Cell Biochem Funct. 2025 Sep;43(9):e70115. doi: 10.1002/cbf.70115.
The study was to evaluate the diagnostic significance of serum miR-125a in individuals with carotid artery stenosis (CAS) and its predictive capacity for cerebral ischemic events (CIEs). This study enrolled 116 healthy controls and 122 CAS patients. Serum miR-125a levels were quantified via RT-qPCR. Receiver operating characteristic (ROC) curve was utilized to evaluate the diagnostic value of miR-125a in differentiating CAS patients from healthy subjects. Logistic regression analysis was performed to explore the association between miR-125a levels and the severity of CAS. Kaplan-Meier (K-M) survival analysis and Cox regression were employed to evaluate the predictive value of miR-125a for the incidence of CIEs throughout the follow-up period. Serum miR-125a level was upregulated in CAS patients compared with controls. ROC curve analysis showed AUC of 0.931 for miR-125a in distinguishing CAS patients. Logistic regression identified miR-125a and low HDL levels as independent risk factors for severe stenosis. Cox regression analysis showed that high miR-125a expression was an independent predictor of CIEs, along with severe stenosis and low HDL. Serum miR-125a serves as a highly specific biomarker for early CAS diagnosis and predicts the risk of CIEs, providing a novel molecular target for CAS risk stratification and clinical intervention.
本研究旨在评估血清miR-125a在颈动脉狭窄（CAS）患者中的诊断意义及其对脑缺血事件（CIE）的预测能力。本研究纳入了116名健康对照者和122名CAS患者。通过逆转录定量聚合酶链反应（RT-qPCR）对血清miR-125a水平进行定量。采用受试者工作特征（ROC）曲线评估miR-125a在区分CAS患者与健康受试者方面的诊断价值。进行逻辑回归分析以探讨miR-125a水平与CAS严重程度之间的关联。采用Kaplan-Meier（K-M）生存分析和Cox回归评估miR-125a在整个随访期对CIE发生率的预测价值。与对照组相比，CAS患者血清miR-125a水平上调。ROC曲线分析显示，miR-125a区分CAS患者的曲线下面积（AUC）为0.931。逻辑回归确定miR-125a和低高密度脂蛋白（HDL）水平是重度狭窄的独立危险因素。Cox回归分析表明，高miR-125a表达是CIE的独立预测因素，同时还有重度狭窄和低HDL。血清miR-125a可作为早期CAS诊断的高度特异性生物标志物，并预测CIE风险，为CAS风险分层和临床干预提供了新的分子靶点。
